Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

[en] CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Fogli, Stefano

Del Re, Marzia

Curigliano, Giuseppe

van Schaik, Ron H.

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Danesi, Romano

Language :

English

Title :

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Publication date :

2019

Journal title :

Cancer Treatment Reviews

ISSN :

0305-7372

eISSN :

1532-1967

Publisher :

W. B. Saunders Co., United Kingdom

Volume :

Pages :

21-28

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 07 April 2019

Statistics

Number of views

672 (5 by ULiège)

Number of downloads

2176 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

VanArsdale, T., Boshoff, C., Arndt, K.T., Abraham, R.T., Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res 21 (2015), 2905–2910, 10.1158/1078-0432.CCR-14-0816.
Chen, P., Lee, N.V., Hu, W., Xu, M., Ferre, R.A., Lam, H., et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther 15 (2016), 2273–2281, 10.1158/1535-7163.MCT-16-0300.
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget 8 (2017), 69493–69507, 10.18632/oncotarget.17778.
Lim, J.S.J., Turner, N.C., Yap, T.A., CDK4/6 Inhibitors: promising opportunities beyond Breast Cancer. Cancer Discov 6 (2016), 697–699, 10.1158/2159-8290.CD-16-0563.
Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548 (2017), 471–475, 10.1038/nature23465.
Deng, J., Wang, E.S., Jenkins, R.W., Li, S., Dries, R., Yates, K., et al. CDK4/6 Inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov 8 (2018), 216–233, 10.1158/2159-8290.CD-17-0915.
Schaer, D.A., Beckmann, R.P., Dempsey, J.A., Huber, L., Forest, A., Amaladas, N., et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep 22 (2018), 2978–2994, 10.1016/j.celrep.2018.02.053.
LeBlanc, T.W., McNeil, M.J., Kamal, A.H., Currow, D.C., Abernethy, A.P., Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 16 (2015), e333–e341, 10.1016/S1470-2045(15)00080-7.
Flaherty, K.T., Lorusso, P.M., Demichele, A., Abramson, V.G., Courtney, R., Randolph, S.S., et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18 (2012), 568–576, 10.1158/1078-0432.CCR-11-0509.
Sun, W., Klamerus, K.J., Yuhas, L.M., Pawlak, S., Plotka, A., O'Gorman, M., et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with ph-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev 6 (2017), 614–626, 10.1002/cpdd.356.
de Gooijer, M.C., Zhang, P., Thota, N., Mayayo-Peralta, I., Buil, L.C.M., Beijnen, J.H., et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs 33 (2015), 1012–1019, 10.1007/s10637-015-0266-y.
Raub, T.J., Wishart, G.N., Kulanthaivel, P., Staton, B.A., Ajamie, R.T., Sawada, G.A., et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos 43 (2015), 1360–1371, 10.1124/dmd.114.062745.
Tripathy, D., Bardia, A., Sellers, W.R., Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res 23 (2017), 3251–3262, 10.1158/1078-0432.CCR-16-3157.
Samant, T.S., Dhuria, S., Lu, Y., Laisney, M., Yang, S., Grandeury, A., et al. Bioavailability is not affected by gastric pH changes or food intake. In silico and clinical evaluations. Clin Pharmacol Ther 19 (2017), 6173–6383, 10.1002/cpt.940.
Infante, J.R., Cassier, P.A., Gerecitano, J.F., Witteveen, P.O., Chugh, R., Ribrag, V., et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res 22 (2016), 5696–5705, 10.1158/1078-0432.CCR-16-1248.
Tate, S.C., Sykes, A.K., Kulanthaivel, P., Chan, E.M., Turner, P.K., Cronier, D.M., A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin Pharmacokinet 57 (2018), 335–344, 10.1007/s40262-017-0559-8.
Lohr, L., Abemaciclib (verzenio™). Oncology Times 40 (2018), 12–329, 10.1097/01.COT.0000531949.12609.f1.
Patnaik, A., Rosen, L.S., Tolaney, S.M., Tolcher, A.W., Goldman, J.W., Gandhi, L., et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6 (2016), 740–753, 10.1158/2159-8290.CD-16-0095.
Kassem, L., Shohdy, K.S., Lasheen, S., Abdel-Rahman, O., Bachelot, T., Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer 25 (2018), 17–27, 10.1007/s12282-017-0818-4.
Hu, W., Abstract 1635: mechanistic investigation of neutropenia associated with palbociclib. Cancer Res 75 (2015), 1635–1645, 10.1158/1538-7445.AM2015-1635.
Spring, L.M., Zangardi, M.L., Moy, B., Bardia, A., Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 22 (2017), 1039–1048, 10.1634/theoncologist.2017-0142.
Shohdy, K.S., Lasheen, S., Kassem, L., Abdel-Rahman, O., Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis. Therapeutic Adv Drug Saf 8 (2017), 337–347, 10.1177/2042098617722516.
Kotake, T., Toi, M., Abemaciclib for the treatment of breast cancer. Expert Opin Pharmacother 19 (2018), 517–524, 10.1080/14656566.2018.1448787.
Lasheen, S., Shohdy, K.S., Kassem, L., Abdel-Rahman, O., Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther 17 (2017), 851–856, 10.1080/14737140.2017.1355242.
Vandael, E., Vandenberk, B., Vandenberghe, J., Spriet, I., Willems, R., Foulon, V., Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39 (2017), 424–432, 10.1007/s11096-017-0446-2.
Coppola, C., Rienzo, A., Piscopo, G., Barbieri, A., Arra, C., Maurea, N., Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev 63 (2018), 135–143, 10.1016/j.ctrv.2017.11.009.
Lamothe, S.M., Guo, J., Li, W., Yang, T., Zhang, S., The human ether-a-go-go-related Gene (hERG) potassium channel represents an unusual target for protease-mediated damage. J Biol Chem 291 (2016), 20387–20401, 10.1074/jbc.M116.743138.
Kaakeh, Y., Overholser, B.R., Lopshire, J.C., Tisdale, J.E., Drug-induced atrial fibrillation. Drugs 72 (2012), 1617–1630, 10.2165/11633140-000000000-00000.
Baxter K. Stockley's Drug Interactions; 2010.
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44 (2005), 279–304.
Patel, A.M., Shariff, S., Bailey, D.G., Juurlink, D.N., Gandhi, S., Mamdani, M., et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Int Med 158 (2013), 869–876, 10.7326/0003-4819-158-12-201306180-00004.
Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52 (2011), e56–e93, 10.1093/cid/cir073.
Kulanthaivel, P., Mahadevan, D., Turner, P.K., Royalty, J., Ng, W.T., Yi, P., et al. Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res, 76, 2016, 10.1158/1538-7445.AM2016-CT153.
Niwa, T., Morimoto, M., Hirai, T., Hata, T., Hayashi, M., Imagawa, Y., Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci 41 (2016), 143–146, 10.2131/jts.41.143.
Bellmann, R., Smuszkiewicz, P., Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45 (2017), 737–779, 10.1007/s15010-017-1042-z.
Niwa, T., Imagawa, Y., Yamazaki, H., Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab 15 (2014), 651–679.
Pantanowitz, L., Dezube, B.J., Breast cancer in women with HIV/AIDS. JAMA 285 (2001), 3090–3091.
Voutsadakis, I.A., Silverman, L.R., Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest 20 (2002), 452–457.
Wu, T., Chen, Z., To, K.K.W., Fang, X., Wang, F., Cheng, B., et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol 124 (2017), 29–42, 10.1016/j.bcp.2016.10.015.
Zolnerciks, J.K., Booth-Genthe, C.L., Gupta, A., Harris, J., Unadkat, J.D., Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. J Pharm Sci 100 (2011), 3055–3061, 10.1002/jps.22566.
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., Richter von, O., Zundler, J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104 (1999), 147–153, 10.1172/JCI6663.
Miyama, T., Takanaga, H., Matsuo, H., Yamano, K., Yamamoto, K., Iga, T., et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 42 (1998), 1738–1744.
Schwartz, P.J., Woosley, R.L., Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 67 (2016), 1639–1650, 10.1016/j.jacc.2015.12.063.
Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De Laurentiis, M., Im, S.-A., et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, JCO2018789909, 2018, 10.1200/JCO.2018.78.9909.
Puppe, J., van Ooyen, D., Neise, J., Thangarajah, F., Eichler, C., Krämer, S., et al. Evaluation of QTc interval prolongation in breast cancer patients after treatment with epirubicin, cyclophosphamide, and docetaxel and the influence of interobserver variation. Breast Care (Basel) 12 (2017), 40–44, 10.1159/000455065.
Barni, S., Petrelli, F., Cabiddu, M., Cardiotoxicity of antiemetic drugs in oncology: an overview of the current state of the art. Crit Rev Oncol Hematol 102 (2016), 125–134, 10.1016/j.critrevonc.2016.04.012.
Swarm, R.A., Abernethy, A.P., Anghelescu, D.L., Benedetti, C., Buga, S., Cleeland, C., et al. Adult cancer pain. J Natl Compr Canc Netw 11 (2013), 992–1022.
Raffa, R.B., Burmeister, J.J., Yuvasheva, E., Pergolizzi, J.V., QTc interval prolongation by d-propoxyphene: what about other analgesics?. Expert Opin Pharmacother 13 (2012), 1397–1409, 10.1517/14656566.2012.682150.
Alinejad, S., Kazemi, T., Zamani, N., Hoffman, R.S., Mehrpour, O., A systematic review of the cardiotoxicity of methadone. Excli J 14 (2015), 577–600, 10.17179/excli2015-553.
Massarella, J., Ariyawansa, J., Natarajan, J., Francke, S., Murtaugh, T., DeLemos, B., et al. Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults. Clin Pharmacol Drug Dev, 95, 2018, 915, 10.1002/cpdd.473.
Oh, C., Rengelshausen, J., Mangold, B., Etropolski, M., Rauschkolb, C., Wang, S.S., et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther 48 (2010), 678–687.
Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C., Hotopf, M., Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev, 4, 2018, CD011006, 10.1002/14651858.CD011006.pub3.
Albert, R.K., Schuller, J.L., COPD clinical research network. macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 189 (2014), 1173–1180, 10.1164/rccm.201402-0385CI.
Han, S., Zhang, Y., Chen, Q., Duan, Y., Zheng, T., Hu, X., et al. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking. Eur J Pharmacol 650 (2011), 138–144, 10.1016/j.ejphar.2010.10.010.
Berger, F.A., Monadian, N., de Groot, N.M.S., Santbergen, B., van der Sijs, H., Becker, M.L., et al. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors. Br J Clin Pharmacol 84 (2018), 369–378, 10.1111/bcp.13457.
Srinivas, N.R., Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs R D 16 (2016), 141–148, 10.1007/s40268-016-0133-0.
Fichtenbaum, C.J., Gerber, J.G., Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41 (2002), 1195–1211, 10.2165/00003088-200241140-00004.
Tadesse, S., Yu, M., Mekonnen, L.B., Lam, F., Islam, S., Tomusange, K., et al. Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. J Med Chem 60 (2017), 1892–1915, 10.1021/acs.jmedchem.6b01670.
Flockhart, D.A., Oesterheld, J.R., Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 9 (2000), 43–76.
Woosley, R.L., Black, K., Heise, C.W., Romero, K., CredibleMeds.org: What does it offer?. Trends Cardiovasc Med 28 (2018), 94–99, 10.1016/j.tcm.2017.07.010.